PharmaGap Lead Drug to Be Presented at American Association for Cancer Research 102nd Annual Meeting
February 11 2011 - 8:30AM
Marketwired
PharmaGap Inc. (TSX VENTURE: GAP)(OTCBB: PHRGF) ("PharmaGap" or
"the Company") announced today that the Dr. Ken Sokoll, Vice
President Clinical Development and Chief Operating Officer for
PharmaGap, along with Dr. Barbara Vanderhyden of the Ottawa
Hospital Research Institute ("OHRI"), will be presenting results of
testing of PharmaGap's lead cancer drug in two separate poster
sessions at the American Association for Cancer Research ("AACR")
102nd Annual Meeting in April in Orlando, Florida.
The poster to be presented by PharmaGap is entitled "A Novel PKC
inhibitor: Inhibition of Cell Proliferation in Cancer Cell Lines
and Pharmacokinetics in Sprague-Dawley Rats". This poster presents
further evidence of the ability of GAP-107B8 to inhibit in vitro
cell proliferation in various cancer cells. Using two different
routes of administration (single bolus injection and continuous
infusion) of GAP-107B8 to Sprague Dawley rats has enabled PharmaGap
to gather the first pharmacokinetics data for GAP-107B8 following
administration in animals. These data provide insight into
important parameters such as the half-life, distribution,
metabolism and elimination of GAP-107B8 when administered via the
intravenous route.
The poster to be presented by the Barbara Vanderhyden lab at
OHRI is entitled "Therapeutic Testing of a Novel Inhibitor
GAP-107B8 on Ovarian Cancer Cells", and is the product of the
ongoing collaboration among Dr. Vanderhyden, the OHRI, and
PharmaGap in developing GAP-107B8 for use in treating ovarian
cancer. In addition to previously announced results from this
program showing efficacy against ovarian cancer cell proliferation
in both in vitro and in vivo models, the poster will present
results indicating the effect of GAP-107B8 in inducing apoptosis
(programmed cell death), in blocking or delaying progression of
ovarian cancer cells through their normal cell cycle and in the
reduction of average tumor size due to its therapeutic
efficacy.
The AACR 102nd Annual Meeting 2011 will be held from April 2nd
to 6th in Orlando, Florida. The AACR gives exhibitors the
opportunity to gain visibility for their organizations among more
than 18,000 scientists and other cancer professionals who are
projected to attend from around the world, and is considered to be
the premier networking event for specialists in all areas of cancer
research.
About OHRI and Dr. Barbara Vanderhyden
The Ottawa Hospital Research Institute (OHRI) is the research
arm of The Ottawa Hospital and is an affiliated institute of the
University of Ottawa, closely associated with the University's
Faculties of Medicine and Health Sciences. The OHRI includes more
than 1,500 scientists, clinical investigators, graduate students,
postdoctoral fellows and staff conducting research to improve the
understanding, prevention, diagnosis and treatment of human
disease. www.ohri.ca
Dr. Vanderhyden is a Senior Scientist, Cancer Therapeutics at
the Ottawa Hospital Research Institute and a Professor in the
Departments of Cellular & Molecular Medicine and Obstetrics
& Gynecology at the University of Ottawa. She holds the Corinne
Boyer Chair in Ovarian Cancer Research. She has published over 60
peer-reviewed journal papers primarily in the area of ovarian
cancer and collaborates extensively with many pharmaceutical and
biotechnology companies focused on the development of therapies for
ovarian cancer.
About PharmaGap Inc.
PharmaGap Inc. (TSX VENTURE: GAP), based in Ottawa, ON, is a
biotechnology company with a core focus on developing novel peptide
therapeutics for the treatment of cancer. PharmaGap's GAP-107B8 is
a novel peptide drug that has been shown to be highly cytotoxic to
numerous cancer types, including chemo-resistant cancers, in vitro.
For more information on PharmaGap please visit the Company's
website at www.pharmagap.com.
Forward Looking Statements
This news release contains certain statements that constitute
forward-looking statements as they relate to the Company and its
management. Forward-looking statements are not historical facts but
represent management's current expectations of future events, and
can be identified by words such as "believe", "expects", "will",
"intends", "plans", "projects", "anticipates", "estimates",
"continues", and similar expressions. Although management believes
that expectations represented in such forward-looking statements
are reasonable, there can be no assurance that they will prove to
be correct.
By their nature, forward-looking statements include assumptions
and are subject to inherent risks and uncertainties that could
cause actual future results, conditions, actions or events to
differ materially from those in the forward-looking statements. If
and when forward-looking statements are set out in this news
release, PharmaGap will also set out the material risk factors or
assumptions used to develop the forward-looking statements. Except
as expressly required by applicable securities laws, the Company
assumes no obligation to update or revise any forward-looking
statements. The future outcomes that relate to forward-looking
statements may be influenced by many factors, including, but not
limited to: results of ongoing product testing and development;
regulatory approvals required to complete development of products;
ability to manufacture product at quality and scale for human use
on an economically sound basis; patient reimbursement by private
and public health insurance programs; unintended side effects of
products; competitive products; product liability; intellectual
property; reliance on key personnel; risks of future legal
proceedings; income tax matters; availability and terms of
financing; distribution of securities; effect of market interest
rates on price of securities, and potential dilution.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release. No Securities Commission or other
regulatory authority having jurisdiction over PharmaGap has
approved or disapproved of the information contained herein. This
release contains forward looking statements that may not occur or
may change materially.
Contacts: PharmaGap Inc. Robert McInnis President & CEO
613-990-9551 bmcinnis@pharmagap.com
Pharmagap Inc. (TSXV:GAP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Pharmagap Inc. (TSXV:GAP)
Historical Stock Chart
From Jul 2023 to Jul 2024